NICE approves rituximab for treatment of rare vascular condition

NICE has ruled that rituximab (MabThera) can be considered for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis when used within its marketing authorisation and provided the patient meets certain eligibility criteria.

Rituximab should be available on the NHS for this condition within 3 months of this guidance being issued | SCIENCE PHOTO LIBRARY
Rituximab should be available on the NHS for this condition within 3 months of this guidance being issued | SCIENCE PHOTO LIBRARY

MabThera (rituximab) is licensed for use in combination with glucocorticoids for induction treatment of ANCA-associated vasculitis (defined as severely active granulomatosis with polyangiitis [also known as Wegener's granulomatosis] and microscopic polyangiitis).

To be eligible for treatment with rituximab, the patient must meet one of the following conditions:

  • further treatment with cyclophosphamide would exceed the maximum cumulative dose 
  • cyclophosphamide is contraindicated or not tolerated 
  • the person has not completed their family and cyclophosphamide may affect their fertility
  • the condition has remained active or worsened after a course of cyclophosphamide lasting 3-6 months 
  • the person has had uroepithelial malignancy.

View MabThera drug record

NICE guidance on rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis (TA308)

Follow MIMS on Twitter


Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases